State Street’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $610M | Sell |
|
|||||
|
2025
Q2 | $562M | Sell |
|
|||||
|
2025
Q1 | $538M | Sell |
|
|||||
|
2024
Q4 | $668M | Sell |
|
|||||
|
2024
Q3 | $593M | Buy |
|
|||||
|
2024
Q2 | $634M | Buy |
|
|||||
|
2024
Q1 | $550M | Sell |
|
|||||
|
2023
Q4 | $535M | Buy |
|
|||||
|
2023
Q3 | $432M | Sell |
|
|||||
|
2023
Q2 | $373M | Buy |
|
|||||
|
2023
Q1 | $385M | Buy |
|
|||||
|
2022
Q4 | $446M | Sell |
|
|||||
|
2022
Q3 | $400M | Sell |
|
|||||
|
2022
Q2 | $368M | Buy |
|
|||||
|
2022
Q1 | $350M | Buy |
|
|||||
|
2021
Q4 | $317M | Buy |
|
|||||
|
2021
Q3 | $332M | Buy |
|
|||||
|
2021
Q2 | $332M | Buy |
|
|||||
|
2021
Q1 | $318M | Buy |
|
|||||
|
2020
Q4 | $237M | Buy |
|
|||||
|
2020
Q3 | $219M | Sell |
|
|||||
|
2020
Q2 | $279M | Sell |
|
|||||
|
2020
Q1 | $217M | Buy |
|
|||||
|
2019
Q4 | $264M | Buy |
|
|||||
|
2019
Q3 | $165M | Sell |
|
|||||
|
2019
Q2 | $157M | Sell |
|
|||||
|
2019
Q1 | $178M | Buy |
|
|||||
|
2018
Q4 | $131M | Buy |
|
|||||
|
2018
Q3 | $205M | Sell |
|
|||||
|
2018
Q2 | $174M | Sell |
|
|||||
|
2018
Q1 | $159M | Sell |
|
|||||
|
2017
Q4 | $154M | Sell |
|
|||||
|
2017
Q3 | $151M | Sell |
|
|||||
|
2017
Q2 | $125M | Buy |
|
|||||
|
2017
Q1 | $112M | Buy |
|
|||||
|
2016
Q4 | $88.6M | Buy |
|
|||||
|
2016
Q3 | $109M | Buy |
|
|||||
|
2016
Q2 | $87.1M | Sell |
|
|||||
|
2016
Q1 | $106M | Buy |
|
|||||
|
2015
Q4 | $123M | Buy |
|
|||||
|
2015
Q3 | $80.4M | Sell |
|
|||||
|
2015
Q2 | $97.4M | Buy |
|
|||||
|
2015
Q1 | $79.3M | Sell |
|
|||||
|
2014
Q4 | $46.6M | Sell |
|
|||||
|
2014
Q3 | $34.7M | Buy |
|
|||||
|
2014
Q2 | $32.2M | Sell |
|
|||||
|
2014
Q1 | $36.1M | Sell |
|
|||||
|
2013
Q4 | $25.7M | Sell |
|
|||||
|
2013
Q3 | $31.9M | Buy |
|
|||||
|
2013
Q2 | $27.1M | Buy |
|